Home
overview

SMi is proud to announce the 12th Annual RNA Therapeutics Virtual Conference taking place on 10 - 11 February 2021


RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

Join us in February 2021, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications.
 

RNA Therapeutics 2021 will explore industry insights into how mRNA is being used to combat COVID-19. Engage in case studies exploring the growing therapeutic potential of RNA for rare diseases, delve into future trends in AI application for optimal RNA therapeutics and hear regulatory outlooks of the RNA landscape, clinical trials and looking ahead.

The SMi Virtual Conference Platform will deliver the following benefits:

  • Live and On Demand speaker content: Get access to the latest strategies and case studies from your market place online!
  • Network with all the event attendees: Connect, see who’s attending, chat and share contact details with all online delegates, speakers and sponsors
  • Exhibit a Virtual Booth: You can pack your customized booth full of documents, videos and even show who is manning the booth during the event and hosting meetings
  • Host & Join Meetings & Socials: Join preferred speaking sessions, host you own meetings and even a virtual Networking social, with in built Zoom functionality

Key Job Titles include:

  • Research & Development Directors/Managers/Scientists
  • Heads of Clinical Development
  • Heads of Pre-Clinical Development
  • Head of RNA Biology
  • Head of RNA Formulation and Drug Delivery
  • Head of Pre-clinical R&D
  • Head of New Modalities
  • Head of Discovery
  • Senior Scientists
  • Chief Scientific Officers
  • Chief Medical Officers


Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.
 

Advanced Cell Diagnostics, A Bio-Techne Brand; Aldevron; Aldevron Llc; AMBR Consulting Ltd; AmpTec GmbH; Asahi Kasei Corporation; Astrazeneca; Bachem; BianoGMP; BioNTech RNA Pharmaceuticals; Bio-Techne Ltd; Chiesi Farmaceutici spa; eTheRNA; Ethris GmbH; F.Hoffmann-La Roche AG; Galapagos; GE Healthcare; Genevant Sciences; Genmab A/S; GSK; himed; Imperial College London; Inabata France S.A.S.; Independent; InteRNA Technologies BV; Intertek; Intertek Pharmaceutical Services Manchester; JSC R-PHARM; MHRA; Miescher Pharma GmbH; MiNA Therapeutics; MiNa Therapeutics Ltd; moderna Therapeutics; Nanogenics Ltd; New England Biolabs; NHS Blood and Transplant; NHS Blood and Transplant Authority; Nippon Fine Chemical; Nitto Avecia; Nitto Denko Avecia; Norinnova Technology Transfer AS; Pantherna Therapeutics GmbH; Polyplus-Transfection; Roche Diagnostics Deutschland; Roche Diagnostics Deutschland GmbH; Roche Innovation Center; Royal College of Surgeons in Ireland; Sanofi; Sense Biopharma AS; Symbiosis Pharmaceutical Services Limited; Thermo Fisher Scientific; TranSINE Therapeutics; Univeristy of Gent – Gene Therapy; University Gent; Vaccitech Ltd;

Conference programme

8:00 Registration & Coffee

9:00 Chair's Opening Remarks

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
View Bio

9:10 Approaches for Next Generation Lipid Nanoparticle Technologies for RNA Delivery

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
View Bio

  • Lipid nanoparticles comprising ionizable lipids are versatile delivery systems for therapeutic application of RNA
  • Although having been already successfully translated into clinical practice, there is need for further development of this technology in order to allow its application in a wider range of therapeutic settings
  • Here we present approaches for engineering m-RNA LNPs with improved biological activity and safety
  • The systems may be promising for development of next generation potent and safe RNA therapeutics for clinical translation
  • 9:45 Update on the regulatory environment for clinical trials in the UK

    Kirsty Wydenbach

    Kirsty Wydenbach, Senior Medical Assessor / Deputy Unit Manager , MHRA
    View Bio

  • Changes to the regulation of clinical trials in the UK since January 2021
  • Novel clinical trials and MHRA advice services
  • The future of the MHRA
  • 10:20 Advancing technologies in oligonucleotide delivery - case studies

    Michael Mulqueen

    Michael Mulqueen, VP Business Development, eTheRNA Immunotherapies
    View Bio

  • Lipid nanoparticles for mRNA delivery to lymphoid organs
  • Oncolysis and tumour microenvironment modulating technology
  • Immunostimulation technology to boost the immune response through the dendritic cell pathway
  • Applications for novel oligonucleotide delivery approaches
  • 10:55 Morning Coffee

    11:25 Advances in the biological understanding of lipid nanoparticle delivery to different cell types

    Arpan Desai

    Arpan Desai, Team Leader, Astrazeneca
    View Bio

  • A new machine learning based biological profiling approach to accelerate LNP optimisation
  • Application of biological profiling to optimise LNPs for liver delivery
  • Using biological profiling to understand intracellular delivery to different tumour cell types
  • 12:00 Oligonucleotides as a therapeutic option for Duchenne Muscular Dystrophy (DMD)

    Andre  Müller-York

    Andre Müller-York, Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH

  • Background for the oligonucleotides PMOs / PPMOs and the MoA for RNA-exon skipping
  • I.v. PMOs / PPMOs for RNA-exon skipping in DMD
  • Clinical results for the PMOs / PPMOs from the Sarepta pipeline in DMD
  • 12:35 Novel Therapies for Inherited Retinal Diseases

    Jennifer Pluim

    Jennifer Pluim, Vice President Medical Afffairs, ProQR
    View Bio

  • An overview of ProQR’s RNA therapies platform
  • Sepofarsen (QR-110) for Leber’s Congenital Amaurosis (LCA10)
  • QR-421a for Usher syndrome Exon 13
  • QR-1123 for P23H autosomal dominant RP
  • QR-504a for Fuchs Endothelial Corneal Dystrophy
  • 13:10 Networking Lunch

    13:55 Moving cardiovascular noncoding RNA therapeutics towards clinical reality

    Thomas Thum

    Thomas Thum, Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
    View Bio

  • Innovative approaches to discover noncoding RNAs in cardiovascular disease
  • Testing noncoding RNAs in large animal models
  • Design of adaptive clinical studies using noncoding RNA modulators
     
  • 14:30 RNA immunotherapies: developing cancer vaccines against immunogenic neoantigens

    Wigard Kloosterman

    Wigard Kloosterman, CSO, Frame Therapeutics

  • A collaboration with the aim to develop a new generation of cancer vaccines via RNA
  • New developments in immunology have made immunotherapy of cancer a new treatment option
  • An overview of the technology and potential for further oncology therapeutics
  • 15:05 Self-amplifying mRNA (SAM) vaccines

    Dong Yu

    Dong Yu, Fellow, Senior Director, and Head, GSK Vaccines
    View Bio

  • Overview the principal and preclinical program of the GSK self-amplifying RNA program, illustrated by specific examples
  • Update the progress on its technical development
  • Potentially discuss the clinical POC of the platform
  • 15:40 Afternoon Tea

    16:10 Self-deliverable RNAi ex-vivo and in-vivo

    16:45 Delivery of Novel siRNA constructs for treating cancer

    David Evans

    David Evans, Chief Scientific Officer, Sirnaomics, Inc

  • Creating novel siRNA constructs for cancer treatment
  • Addressing the challenges of cell-specific delivery: how to get size and efficacy right?
  • Choosing the appropriate delivery system
  • Steps taken towards validation of novel constructs
  • 17:20 Chair’s Closing Remarks

    Heinrich Haas

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
    View Bio

    8:00 Registration & Coffee

    9:00 Chair's Opening Remarks

    Heinrich Haas

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
    View Bio

    9:10 Targeted Nucleic Acid therapeutics

    Shalini Andersson

    Shalini Andersson, Chief Scientist New Therapeutic Modalitiesand Head of Oligonucleotide Discovery, AstraZeneca

  • Concept of targeted delivery of nucleic acid therapeutics
  • Different targeting approaches and impact on efficacy and therapeutic window
  • Utility of targeted delivery in pre-clinical and clinical drug development
  • Future direction
  • 9:45 Therapeutic development using chemically modified asymmetric small interfering RNAs

    Dong-Ki Lee

    Dong-Ki Lee, CEO, OilX Pharmaceuticals

  • RNA interference (RNAi)-based gene silencing has become the 3rd therapeutic development platform with multiple FDA-approved RNAi drugs on market
  • Asymmetric siRNA (asiRNA) triggers efficient target gene silencing with reduced non-specific effects
  • OliX Pharmaceuticlas has developed cp-asiRNA for local administration therapeutics, and GalNAc-asiRNA for liver targeting therapeutics
  • Will describe OliX Pharmaceuticals’ pre-clinical and clinical developments against various disease indications
  • 10:20 MiRNA Therapeutics: From Bench to Bedside

    Ekkehard Leberer

    Ekkehard Leberer, Senior Director, Global Alliance Management, Sanofi

  • MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of pathways by the mechanism of RNA interference (RNAi).
  • MicroRNA-21 has been implicated in multiple organs as a microRNA associated with fibrotic diseases and cancer.
  • We have generated an anti-fibrotic microRNA-based therapeutic approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21).
  • This microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport Syndrome
  • 10:55 Morning Coffee

    11:25 Progress in microRNA therapeutics for epilepsy and rare neurodevelopmental disorders

    Cristina Reschke

    Cristina Reschke, Lecturer, Royal College of Surgeons in Ireland

  • Background covering epilepsy (TLE and epilepsy as a common comorbidity in rare neurodevelopmental disorders).
  • Concepts about miRNA and functional assessments.
  • Pre-clinical journey of miR-134 inhibitor (Ant-134) in models of adult TLE
  • Pre-clinical assessment of Ant-134 in Angelman & Dravet syndromes
  • 12:00 RNA Therapeutics: Consolidation and New Aspects

    Troels Koch

    Troels Koch, CEO & Founder, Aqiventa
    View Bio

  • RNA therapeutics is experiencing increasing interest and growth. Modality wise, this is mainly driven by different oligonucleotide modalities that have matured and reached important market approvals
  • The field is also experiencing a technology/modality competition race where some technologies are found to be superior over others - in the same areas.
  • This consolidation is a result of many years R&D from which strengths and weaknesses of the different modalities have been studied and identified 
  • The talk will illustrate this development, but also show new data on how computational methods can be used to get a better understanding of the structure & nature of oligonucleotides, and how this methodology can be used to guide drug discovery
  • 12:35 AI Application of Drug Discovery for Triple Negative Breast Cancer

    Maria Luisa Pineda

    Maria Luisa Pineda, CEO and Co-founder, Envisagenics
    View Bio

  • Envisagenics’ software platform, SpliceCore, integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific alternatively spliced RNA that will function as therapeutic targets 
  • Discovery of novel TNBC specific splicing isoforms
  • Designing optimal RNA-therapeutics targeting TNBC specific splicing isoforms using machine learning
  • Experimental qualification and validation of ASOs designed by SpliceCore
  • 13:10 Networking Lunch

    13:55 Evolution, challenges and potential of RNA Therapeutics

    Ruchi Shah

    Ruchi Shah, Senior Research Engineer, Eli Lilly and Company
    View Bio

  • Background on RNA Therapeutics –what it encompasses, current status and pipeline
  • Challenges surrounding development of RNA Therapeutics
  • Promising future of RNA therapeutics
  • 14:30 RNA Nanotechnology Unlocks The Potential of Small RNA Therapeutics

    Fengmei Pi

    Fengmei Pi, General Manager and Director of R&D, ExonanoRNA

  • RNA nanoparticles for targeted delivery of anti-miRNA for oncology disease
  • RNA nanoparticles for targeted delivery of chemical drug for oncology disease
  • RNA nanoparticles decorated exosomes for targeted delivery of siRNA
  • Pipeline and plan
  • 15:05 Precision medicine to treat genetic disorders

    Barry Ticho

    Barry Ticho, Chief Medical Officer, Stoke Therapeutics

  • An overview of the TANGO platform and how it works
  • Antisense oligonucleotides for targeted binding to mRNA
  • The challenge of oligonucleotides for non-liver delivery and potential applications for severe genetic diseases affecting the CNS
  • Case Study: Dravet Syndrome
  • 15:40 Afternoon Tea

    16:10 COVID-19: how has the RNA industry adapted to beat the pandemic

  • The global collaboration to facilitate development and evaluation of therapeutics, diagnostics and vaccines against COVID-19
  • Current mRNA vaccines in development
  • How has industry adapted clinical trials and R&D to allow accelerated development?
  • How have approval processes been accelerated and will this affect future approval processes post-pandemic?

     

  • Heinrich Haas

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
    View Bio

    Troels Koch

    Troels Koch, CEO & Founder, Aqiventa
    View Bio

    Kirsty Wydenbach

    Kirsty Wydenbach, Senior Medical Assessor / Deputy Unit Manager , MHRA
    View Bio

    Michael Mulqueen

    Michael Mulqueen, VP Business Development, eTheRNA Immunotherapies
    View Bio

    16:45 mRNA and developing a COVID-19 vaccine

  • An introduction to Arcturus Therapeutics 
  • mRNA technologies and the therapeutic potential
  • An overview of the LUNAR delivery technology
  • Case Study: LUNAR-COV19
  • Priya Karmali

    Priya Karmali, Vice President, Technology Innovation and Development, Arcturus Therapeutics

    17:20 Chair’s Closing Remarks

    Heinrich Haas

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
    View Bio

    +

    FEATURED SPEAKERS

    Arpan Desai

    Arpan Desai

    Team Leader, Astrazeneca
    Dong Yu

    Dong Yu

    Fellow, Senior Director, and Head, GSK Vaccines
    Heinrich Haas

    Heinrich Haas

    VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
    Jennifer Pluim

    Jennifer Pluim

    Vice President Medical Afffairs, ProQR
    Maria Luisa Pineda

    Maria Luisa Pineda

    CEO and Co-founder, Envisagenics
    Michael Mulqueen

    Michael Mulqueen

    VP Business Development, eTheRNA Immunotherapies
    Priya Karmali

    Priya Karmali

    Vice President, Technology Innovation and Development, Arcturus Therapeutics
    Ruchi Shah

    Ruchi Shah

    Senior Research Engineer, Eli Lilly and Company
    Thomas Thum

    Thomas Thum

    Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
    Troels Koch

    Troels Koch

    CEO & Founder, Aqiventa
    Wigard Kloosterman

    Wigard Kloosterman

    CSO, Frame Therapeutics

    Alexey Wolfson

    CEO, Advirna
    Alexey Wolfson

    Andre Müller-York

    Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH
    Andre  Müller-York

    Arpan Desai

    Team Leader, Astrazeneca
    Arpan Desai

    Arpan completed his first degree in Biotechnology at the University of Edinburgh, following which he obtained a PhD from the AZ/University of Nottingham Doctoral Training Centre in Targeted Therapeutics, where he studied the uptake and intracellular trafficking pathways of polymeric nanoparticles using pH-based nanosensors. He joined AZ in 2013 where he has worked primarily in the field of nucleic acid delivery. He has played a leading role in AZs formulation and delivery development activities for therapeutic nucleic acids with a focus on understanding cellular delivery mechanisms of mRNA using non-viral delivery vehicles. He has played a leading role in a number AZs collaborations to develop nucleic acid-based therapeutics including Moderna Therapeutics (mRNA), Ionis (ASOs) and Regulus (anti-miRs). More recently, he has established AZs Nucleic Acid Drug Delivery (NDD) team. This is a global discovery research focused group with the ultimate mission of apply delivery science to help advance nucleic acid based therapies into the clinic.

    Barry Ticho

    Chief Medical Officer, Stoke Therapeutics
    Barry Ticho

    Cristina Reschke

    Lecturer, Royal College of Surgeons in Ireland
    Cristina Reschke

    David Evans

    Chief Scientific Officer, Sirnaomics, Inc
    David Evans

    Dong Yu

    Fellow, Senior Director, and Head, GSK Vaccines
    Dong Yu

    Dr. Dong Yu is a Fellow, Senior Director, and Head of Preclinical R&D US at GSK Vaccines. He leads an organization of >80 scientists driving preclinical R&D of GSK Vaccines portfolio in the US. Dong received his PhD degree from University of Connecticut Health Center and postdoctoral training at Princeton University. He was an assistant professor at Washington University before joining GSK Vaccines (Legacy Novartis Vaccines then) in 2013. Dong has authored >40 peer-reviewed publications and is a recipient of prestigious awards such as the Investigator Award from Burroughs Wellcome and the Howard Temin Award from NIH.

    Dong-Ki Lee

    CEO, OilX Pharmaceuticals
    Dong-Ki Lee

    Ekkehard Leberer

    Senior Director, Global Alliance Management, Sanofi
    Ekkehard Leberer

    Fengmei Pi

    General Manager and Director of R&D, ExonanoRNA
    Fengmei Pi

    Heinrich Haas

    VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
    Heinrich Haas

    Heinrich has more than 20 years of experience in academic research and industrial pharmaceutical development. His focus is on development for advanced drug delivery systems. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems. He was responsible for projects in different biopharmaceutical companies for research and development of diagnostic and therapeutic carrier systems. Joining BioNTech in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules.

    Jennifer Pluim

    Vice President Medical Afffairs, ProQR
    Jennifer Pluim

    Jennifer is Vice President, Medical Affairs at ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases, with a focused drug development on a group of blinding disorders affecting the retina, called inherited retinal diseases. Jennifer has over 25 years’ experience in the pharmaceutical industry, with extensive knowledge in clinical operations, project management and medical affairs. Her experience spans several therapeutic areas, including infectious diseases, respiratory critical care, cardiovascular disease, oncology and ophthalmology. Jennifer earned a B.S. in Microbiology with certification as a Medical Technologist and an MBA from The Pennsylvania State University USA.

    Kirsty Wydenbach

    Senior Medical Assessor / Deputy Unit Manager , MHRA
    Kirsty Wydenbach

    Dr Kirsty Wydenbach is a Senior Medical Assessor and the Deputy Unit Manager in the Clinical Trials Unit, having joined the MHRA in 2009. She has been involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including ATMPs and many first-in-man studies. She has also been involved in European discussions aiming to establish an EU harmonised approach to clinical trials, particularly for Developmental Safety Update Reports (DSURs) and Reference Safety Information (RSI). She was also an EMA expert for the update of the First-in-Human guideline. Other recent work has included collaboration with external industry groups and regulators regarding adaptive and novel trial designs: she is leading on this aspect for the MHRA in order to implement that aspect of the Life Sciences Industrial Strategy, and was a contributor to the EU CTFG “Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials”. More recently Kirsty has overseen the clinical trial work for COVID-19 and provided regulatory expertise on vaccines both within MHRA but also as part of the government Vaccine Taskforce.

    Maria Luisa Pineda

    CEO and Co-founder, Envisagenics
    Maria Luisa Pineda

    Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific splicing variants as therapeutic targets. Envisagenics has leveraged its SpliceCore® software platform for therapeutic development with its first pipeline of assets in triple negative breast cancer. In April, Envisagenics has announced an oncology partnership leveraging SpliceCore with The Lung Cancer Initiative at Johnson & Johnson.

    Michael Mulqueen

    VP Business Development, eTheRNA Immunotherapies
    Michael Mulqueen

    Michael started his career with Roche as part of the business development department with a strong focus on in-licensing and alliance management. He left Roche to set up Synosia Therapeutics AG. From this point on, he worked with a number of European biotech companies with a focus on out-licensing and partnering. Latterly, he was VP for BD and Licensing with Silence Therapeutics in the RNAi field.

    Priya Karmali

    Vice President, Technology Innovation and Development, Arcturus Therapeutics
    Priya Karmali

    Ruchi Shah

    Senior Research Engineer, Eli Lilly and Company
    Ruchi Shah

    Dr. Ruchi Shah received her M.S. and Ph.D in Pharmaceutical Sciences from Northeastern University in Boston, MA, USA. Her graduate work focused on development of lipid-based adjuvants for subunit vaccines in collaboration with the vaccines business of GlaxoSmithKline. Dr. Shah has led formulation and development activities of lipid-based delivery systems for mRNA and CRISPR Cas9 for both vaccines and therapeutics at GlaxoSmithKline Vaccines, Intellia Therapeutics and Moderna Therapeutics. Currently in her role at Eli Lilly and Company, she is a Senior Research Engineer in the New Therapeutics Modalities group to accelerate and develop novel therapies for unmet medical needs.

    Shalini Andersson

    Chief Scientist New Therapeutic Modalitiesand Head of Oligonucleotide Discovery, AstraZeneca
    Shalini Andersson

    Thomas Thum

    Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
    Thomas Thum

    Thomas Thum studied medicine in Hannover, with state examination in 2001 and board examination for internal medicine/cardiology in 2009/2010. He received his PhD at the Imperial College, London (2008). He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies at the Hannover Medical School (MHH), Visiting Professor at the Imperial College, and director of MHH’s Center for Translational Regenerative Medicine. He (co-) authors > 350 publications and is a distinguished reviewer, board member, patent holder, and founder.

    Troels Koch

    CEO & Founder, Aqiventa
    Troels Koch

    Troels Koch (TK) has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche, and Exiqon A/S was acquired in 2016 by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has been responsible for keeping LNA antisense science and technology at an international lead position. He has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.

    Wigard Kloosterman

    CSO, Frame Therapeutics
    Wigard Kloosterman

    Exhibitors

    Supporting Media Partners

    VENUE

    Online Virtual Event

    Online Virtual Event , Online Virtual Event , United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Past Attendee List

    Download

    PAST PRESENTATION - David Blakey - Mina Therapeutics

    Download

    PAST PRESENTATION - Surender Vashist - AstraZeneca

    Download

    PAST PRESENTATION - Klaus Giese - Pantherna Therapeutics

    Download

    PAST PRESENTATION - Heinrich Haas - BioNTech

    Download

    PAST PRESENTATION - Dr. Michel Janicot - InteRNA Technologies

    Download

    PAST PRESENTATION - David. C. Henshall - Royal College of Surgeons of Ireland

    Download

    PAST PRESENTATION - Dr Kirsty Wydenbach - MHRA

    Download

    PAST PRESENTATION - Dr Simon Newman - NanoGenics

    Download

    PAST PRESENTATION - David Deutsch - MHRA

    Download

    PAST PRESENTATION - Christopher Bunker - Advanced Cell Diagnostics

    Download

    PAST PRESENTATION - Bo Rode Hansen, PhD - Genevant Sciences, Inc

    Download

    Exhibitors


    Thermo Fisher Scientific

    Exhibitors
    http://www.thermofisher.com/

    For more than 40 years, Thermo Fisher Scientific has been a leading supplier of nucleic acid based raw materials, products and service for our customers in diagnostics, therapeutics, pharmaceutical and life science companies. With custom solutions to meet our customers unique quality and regulatory requirements, we help them succeed from development to commercialization. Visit our booth and learn about Thermo Scientific custom and OEM capabilities.

    Media Partners


    pharmanews hq

    Supporting Media Partners
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    ASD MEDIA

    Supporting Media Partners
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    Pharmacircle

    Supporting Media Partners
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Pharmavision

    Supporting Media Partners
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharmalicensing

    Supporting Media Partners
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Farmavita

    Supporting Media Partners
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Technology Networks

    Supporting Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Mednous

    Supporting Media Partners
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Gene Therapy Net

    Supporting Media Partners
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    Drug Discovery Today

    Supporting Media Partners
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    pharmaphorum

    Supporting Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out